Genzyme’s Lumizyme REMS Eliminated Due To Expanded Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves Lumizyme for all Pompe disease patients, making it unnecessary to restrict use to a specific age group; Myozyme, produced at a different scale, will remain available.